# Diabetic Macular Edema (DME) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diabetic-macular-edema-dme

> 6 upcoming FDA catalysts in diabetic Macular Edema (DME): oral bge-102 (BIOA) on November 2027 (primary completion); oral bge-102 (BIOA) on Nov 2027 to Feb 2028 (topline data readout); tabirafusp tedromer (KOD) on Aug to Nov 2028 (topline data readout); tabirafusp tedromer (KOD) on August 2028 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 2027 | [Oral bge-102 primary completion](https://sec-api.dev/pdufa/oral-bge-102) | BIOA | Diabetic Macular Edema (DME) | scheduled | "NCT07812090 (A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor BioAge Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07812090)) |
| Nov 2027 to Feb 2028 | [Oral bge-102 topline data readout](https://sec-api.dev/pdufa/oral-bge-102) | BIOA | Diabetic Macular Edema (DME) | scheduled | "NCT07812090 (A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor BioAge Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07812090)) |
| Aug to Nov 2028 | [Tabirafusp tedromer topline data readout](https://sec-api.dev/pdufa/tabirafusp-tedromer) | KOD | Diabetic Macular Edema (DME) | scheduled | "NCT07734844 (A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-31 (ESTIMATED); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07734844)) |
| August 2028 | [Tabirafusp tedromer primary completion](https://sec-api.dev/pdufa/tabirafusp-tedromer) | KOD | Diabetic Macular Edema (DME) | scheduled | "NCT07734844 (A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-31 (ESTIMATED); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07734844)) |
| January 2029 | [4d-150 ivt (3x10^10 vg) primary completion](https://sec-api.dev/pdufa/4d-150-ivt-3x10-10-vg) | FDMT | Diabetic Macular Edema (DME) | scheduled | "NCT07867080 (A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor 4D Molecular Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07867080)) |
| Jan to Apr 2029 | [4d-150 ivt (3x10^10 vg) topline data readout](https://sec-api.dev/pdufa/4d-150-ivt-3x10-10-vg) | FDMT | Diabetic Macular Edema (DME) | scheduled | "NCT07867080 (A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor 4D Molecular Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07867080)) |

## Drugs

- [Oral bge-102](https://sec-api.dev/pdufa/oral-bge-102) (BIOA)
- [Tabirafusp tedromer](https://sec-api.dev/pdufa/tabirafusp-tedromer) (KOD)
- [4d-150 ivt (3x10^10 vg)](https://sec-api.dev/pdufa/4d-150-ivt-3x10-10-vg) (FDMT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diabetic-macular-edema-dme.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diabetic Macular Edema (DME) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diabetic-macular-edema-dme

```bibtex
@misc{secapidev_indications_diabetic_macular_edema_dme_20261116,
  title        = {Diabetic Macular Edema (DME) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diabetic-macular-edema-dme}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diabetic_macular_edema_dme_20261116","title":"Diabetic Macular Edema (DME) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diabetic-macular-edema-dme","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
